Rezum

This BackTable podcast is sponsored by Boston Scientific’s Urology Division. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world; this includes solutions for Benign Prostatic Hyperplasia or BPH, one of the most prevalent urologic conditions facing men today. [1,2]

Boston Scientific’s RezūmTM Water Vapor Therapy is a minimally invasive BPH treatment that provides urologists with an efficient, durable solution that reduces prostate volume while preserving sexual function. [3,4] With proven efficacy, durability, and lower clinical progression rates than daily medications, AUA guidelines support a shared decision-making process for the consideration of RezūmTM as a first-line treatment and alternative to medications. [3,5,6] Additionally, if insufficiently treated, BPH can negatively
impact bladder function, making earlier intervention valuable for patients. [7] Give your patients an alternative to daily medications and long-lasting BPH relief with Rezum Therapy.

1. AUA Annual Census Report – 2021, https://www.auanet.org/research-and-data/aua-census
2. Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016
May 5;2:16031. doi: 10.1038/nrdp.2016.31. PMID: 27147135
3. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of Rezūm water
vapor thermal therapy for treatment of moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J
Urol. 2021 Sep;206(3):715-24.
4. Mynderse LA, Hanson D, Robb RA, et al. Rezūm System water vapor treatment for lower urinary tract symptoms/benign prostatic
hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional
renderings. Urology. 2015 Jul;86(1):122-7.
5. Gupta N, Rogers T, Holland B, et al. Three-year treatment outcomes of water vapor thermal therapy (Rezūm System) compared to
doxazosin, finasteride and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of
Prostatic Symptoms (MTOPS) Trial. J Urol. 2018 Aug;200(2):405-13.
6. Lerner LB, McVary, KT, Barry MJ et al: Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA
Guideline. J Urol 2021; 206: 806.
7. Mirone V, Imbimbo C, Longo N, Fusco F. The Detrusor Muscle: An Innocent Victim of Bladder Outlet Obstruction. J Eur Uro. 2007, Vol 51

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.
All trademarks are the property of their respective owners.
©2023 Boston Scientific Corporation or its affiliates. All rights reserved. URO-1540313-AA MAR 2023

The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.